Authors
Latest:
Exploring the Changing Landscape of ICI Tx in NSCLCIn this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
Latest:
Newer Targeted Approaches in Medullary Thyroid CancerIn this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
Latest:
What Caused This Ulcerated Nodular Skin Lesion in a 30-Year-Old Man?This lesion started as a rash 3 months prior to presentation and became an ulcerated open wound with some nodularity in and around it. What is your diagnosis?
Latest:
Cell-Free DNA Blood Test May Detect Early-Stage Lung CancerCell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.
Latest:
Dr. Daniel George on the Treatment Landscape for RCCCancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Latest:
Newer Targeted Agents in NSCLC: ALK InhibitorsAlice Shaw highlights the development and clinical considerations for use of first- and next-generation ALK inhibitors in NSCLC, plus ongoing research.
Latest:
Andrew J. Armstrong, MD, Details PSMA-PET Scan Parameters Indicating Better Survival Outcomes With 177Lu-PSMA-617 in mCRPCData from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.
Latest:
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 InhibitorRobert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Latest:
Acute Kidney Injury in Patients With CancerAcute kidney injury is a common complication in cancer patients, and clinicians should be familiar with the processes that cause it.
Latest:
Sharing Serious News With Cancer Patients: Strategies That Can HelpThe way in which serious news is discussed significantly affects many outcomes and aspects of patient care. It is important to consider many factors, including those related to patient diversity, such as cultural and family background; language barriers; socioeconomic factors; and health literacy.
Latest:
Sharing Serious News With Cancer Patients: Strategies That Can HelpThe way in which serious news is discussed significantly affects many outcomes and aspects of patient care. It is important to consider many factors, including those related to patient diversity, such as cultural and family background; language barriers; socioeconomic factors; and health literacy.
Latest:
Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy IntensificationA 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?
Latest:
Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy IntensificationA 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?
Latest:
POINT-Prostate Cancer Genomic Analysis: Routine or Research Only?In this side of the Point/Counterpoint, Drs. Bernard and Flaig state that genomic testing should be routine in the management of prostate cancer patients.
Latest:
The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate CancerThis case looks at an otherwise healthy 59-year-old man who was recently diagnosed with clinical stage IVB prostate adenocarcinoma. What is the most appropriate management for this patient?
Latest:
Harnessing the Immunomodulatory Effects of Radiation TherapyIn this article, we discuss radiation’s immunomodulatory effects, with particular attention to the impact of dose and fractionation on the antitumoral response.
Latest:
Using PARP Inhibitors in Advanced Ovarian CancerThe approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.
Latest:
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell LymphomaIn Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
Latest:
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell LymphomaIn Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
Latest:
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell LymphomaIn Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
Latest:
Narjust Duma on How Gender Affects the Tolerability of ImmunotherapyIn this interview, we discuss a study of sex differences in the tolerability of anti–programmed death 1 immunotherapy among patients with metastatic melanoma.
Latest:
Quick but Powerful Tips and Takeways for Nursing Best Practices and Emotional SupportOncology nursing leader Deborah Boyle highlights some essential tips to address common issues in bedside care, staff communication, and on-the-job distress.
Latest:
Germline Testing in Prostate Cancer: When and Who to TestResults of multiple studies have shown that a proportion of men with advanced prostate cancer carry germline DNA damage repair mutations. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.
Latest:
Nurse-Driven Protocol Increased Vaccination for Flu, PneumoniaA pilot protocol developed at Memorial Sloan Kettering Cancer Center resulted in exponential increases in both influenza and pneumococcal vaccinations in the outpatient setting.
Latest:
MGH Program Supports Sexual Health of Women Receiving Pelvic RT for Gastrointestinal and Gynecologic MalignanciesIn an interview with Cancer Network, Lorraine Drapek describes a multidisciplinary program at MGH to support vaginal and sexual health post RT for GI and gynecologic malignancies.
Latest:
Novel Targeted Agents for Lung Cancer: M7824, a Bifunctional Protein Targeting PD-L1 and TGB-β Receptor IIIn a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.
Latest:
How to More Effectively Leverage Cancer Genomics Databases as Clinical Decision–Making ToolsOncologist Dr. Vivek Subbiah and computer scientist Dr. Jason Roszik, both from MD Anderson, discuss optimizing “omics” databases to inform cancer patient care.
Latest:
Perspectives on Overdiagnosis, Overtreatment of Subclinical Thyroid CancersIn an exclusive interview, thyroid cancer expert and surgeon Dr. Louise Davies discusses overdiagnosis and overtreatment of subclinical thyroid cancers.
Latest:
Obese Breast Cancer Patients and Survivors: Management ConsiderationsThis article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.
Latest:
Obese Breast Cancer Patients and Survivors: Management ConsiderationsThis article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.
